This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
==== Carrier matrices ==== Various carrier matrices bound to a solid resin support are on the market and these can be subsequently charged with a metal cation. Derivatives of iminodiacetic acid (IDA) and nitrilotriacetic acid (NTA) are most frequently used for this purpose, with differing matrices having certain advantages and disadvantages for various applications.
NATO categorizes ration packaging under three types: Primary packaging, which is in contact with or contains the food itself (e.g. a can containing food) Secondary packaging, which contains and groups several primary packages (e.g. a retort pouch containing food packages) Tertiary packaging, which contains and groups several secondary packages for storage, shipping, handling, and distribution (e.g. a box containing several rations for distribution)
== Predictive aspects == In a longitudinal evaluation of the NHANES study, a large sample of the general US population, over 10 years, reduced SPINA-DI, calculated as the product of SPINA-GBeta times SPINA-GR, significantly predicted all-cause mortality.
Sources: en.wikipedia.org
==== The shooting of 50 Cent ==== On May 24, 2000, Jackson was shot nine times outside his grandmother's house in connection with a failed robbery attempt. Jackson managed to survive the shooting, though he spent 13 days recovering in the hospital. Adding to existing tension, the attack was reportedly connected to Queens drug lord Kenneth McGriff, who was a known affiliate of Murder Inc. Records. The controversy stemmed from 50 Cent's song "Ghetto Qur'an (Forgive Me)" which had leaked in the spring of 2000. The lyrics directly attacked McGriff and his control over the drug trade in Queens during the 1980s, likely instigating into his own conflict with 50 Cent, culminating in the shooting. Following the attack, problems continued to arise for 50 Cent while he was still hospitalized. The wake of the shooting had cast a negative image for 50 Cent and G-Unit, Columbia Records ultimately chose to drop Jackson and several high-profile labels around New York reportedly blacklisted G-Unit due to the shooting." During this time, Ja Rule had obtained international success as his albums Rule 3:36 and Pain Is Love found widespread commercial success by the beginning of 2002.
=== Cranberry juice === Preliminary research indicates that cranberry juice or capsules may decrease the number of urinary tract infections in women with frequent infections, and a more substantial Cochrane review concludes that there is some evidence that cranberry products reduce the risk of symptomatic urinary tract infections for women, children, and people following intervention, but not for the elderly, people with bladder emptying problems, or pregnant women. Long-term tolerance is also an issue, with gastrointestinal upset occurring in more than 30% of people.
Counter-Strike is a team-based multiplayer first-person shooter video game in which players play as Terrorists (T) or Counter-Terrorists (CT). Each game begins with both teams spawning simultaneously as one of eight possible default character models (four each for Counter-Terrorist and Terrorist). Each player begins with $800, two magazines of ammo, a knife, and a handgun: a Heckler & Koch USP for the Counter-Terrorists or a Glock 18c for the Terrorists. Players are usually allowed a few seconds before the round starts to purchase equipment but not move. They may purchase equipment whenever they are in a buy zone for their team. When players are killed, they become spectators for the rest of the round. They may typically watch the rest of the round from a variety of chosen observer modes. At the end of each round, players receive money for the next round: $3,500 for winning a round, $1,500 for losing one, and $300 for killing an enemy, up to a maximum total of $16,000. Players can be fined, or lose money, by killing a teammate or a hostage. Depending on the map, there are 3 possible objectives to win (in addition to eliminating all enemy team members):
Sources: en.wikipedia.org
=== Brain growth === Neuroanatomical studies and the association between autism and teratogens strongly suggest that autism affects brain development soon after conception. This anomaly appears to start a cascade of pathological events in the brain that are significantly influenced by environmental factors. Just after birth, the brains of children with autism tend to grow faster than usual, followed by normal or relatively slower growth in childhood. It is unknown whether early brain overgrowth occurs in all children with autism. It appears to be most prominent in the frontal and temporal lobes, which are associated with higher cognitive specializations such as social cognition, and language development. Hypotheses for the cellular and molecular bases of pathological early overgrowth include an excess of neurons that causes local overconnectivity in key brain regions, and disturbed neuronal migration during early gestation.
NanoDSF is a type of differential scanning fluorimetry (DSF) method used to determine conformational protein stability by employing intrinsic tryptophan or tyrosine fluorescence, as opposed to the use of extrinsic fluorogenic dyes that are typically monitored via a qPCR instrument. A nanoDSF assay is also known as a type of Thermal Shift Assay. Protein stability is typically addressed by thermal or chemical unfolding experiments. In thermal unfolding experiments, a linear temperature ramp is applied to unfold proteins, whereas chemical unfolding experiments use chemical denaturants in increasing concentrations. The thermal stability of a protein is typically described by the 'melting temperature' or 'Tm', at which 50% of the protein population is unfolded, corresponding to the midpoint of the transition from folded to unfolded. In contrast to conventional DSF methods, nanoDSF uses tryptophan or tyrosine fluorescence to monitor protein unfolding. Both the fluorescence intensity and the fluorescence maximum strongly depend on the close chemical environment of the tryptophan. Typically, interior tryptophan residues in a more hydrophobic environment exhibit a notable emission red shift from approximately 330 nm to 350 nm upon protein unfolding and exposure to water. Quantification of these fluorescence wavelength shifts at various temperature intervals yields a measurement of Tm.
Kennedy, E P (2001), "Hitler's gift and the era of biosynthesis", J. Biol. Chem., vol. 276, no. 46 (published Nov 16, 2001), pp. 42619–31, doi:10.1074/jbc.R100051200, PMID 11559714 Young, V R; Ajami, A (1999), "The Rudolf Schoenheimer Centenary Lecture. Isotopes in nutrition research", The Proceedings of the Nutrition Society, vol. 58, no. 1 (published Feb 1999), pp. 15–32, doi:10.1079/pns19990004, PMID 10343336 Olson, R E (1997), "The dynamic state of body constituents (Schoenheimer, 1939)", J. Nutr., vol. 127, no. 5 Suppl (published May 1997), pp. 1041S–1043S, PMID 9164302 Guggenheim, K Y (1991), "Rudolf Schoenheimer and the concept of the dynamic state of body constituents.", J. Nutr., vol. 121, no. 11 (published Nov 1991), pp. 1701–4, doi:10.1093/jn/121.11.1701, PMID 1941176 Ratner, S; Rittenberg, D; Keston, A S; Schoenheimer, R (1987), "The Journal of Biological Chemistry, Volume 134, June 1940: Studies in protein metabolism. XIV. The chemical interaction of dietary glycine and body proteins in rats. By S. Ratner, D. Rittenberg, Albert S. Keston, and Rudolf Schoenheimer", Nutr. Rev., vol. 45, no. 10 (published Oct 1987), pp. 310–2, doi:10.1111/j.1753-4887.1987.tb06338.x, PMID 3320825 Shemin, D (1987), "On the impact on biochemical research of the discovery of stable isotopes: the outcome of the serendipic meeting of a refugee with the discoverer of heavy isotopes at Columbia University", Anal. Biochem., vol. 161, no. 2 (published Mar 1987), pp.
=== Preclinical === 2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions ART-2612 (ART2612) – FABP5 inhibitor [25] BMB-202 – serotonin 5-HT2A receptor agonist [26] Cycloserine/lurasidone (NRX-101) – combination of cycloserine (NMDA receptor partial agonist) and lurasidone (atypical antipsychotic or non-selective monoamine receptor modulator) [27] Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (H1 receptor antagonist, muscarinic acetylcholine receptor antagonist, serotonin receptor antagonist, other actions) and prazosin (α1-adrenergic receptor antagonist) [28] GM-3009 (ibogaine analogue(s); GMX-3009) – various actions Leu-enkephalin (leucine enkephalin; Envelta; METDoloron; NES-100; NM-0127; NM-127; PES200) – δ-opioid receptor agonist [29] Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor, antiglucocorticoid) and oxazepam (GABAA receptor positive allosteric modulator, benzodiazepine) Midomafetamine microneedle transdermal patch (MDMA; "ecstasy") – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen NB-127 – undefined mechanism of action [30] NNI-351 – DYRK kinase inhibitor, nerve growth factor (NGF) stimulant [31] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent [32] Research programme: neurotransmitter modulators - Awakn Life Sciences (AWKN-SDN-14) – serotonin–norepinephrine–dopamine reuptake inhibitors [33] TN-001 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist and neuroplastogen
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.